{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-018397","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.910146+00:00","generated_at":"2026-05-15T10:17:24.818741+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Precision BioSciences hosts KOL event for PBGENE-DMD DMD program; no new data disclosed","bullets":["KOL event on March 17, 2026 features Dr. Veerapandiyan and Pat Furlong discussing DMD unmet need and treatment landscape.","Overview of PBGENE-DMD gene editing program and FUNCTION-DMD Phase 1/2 trial presented; no new clinical or financial data released.","Presentation materials and webcast replay available on Precision BioSciences investor website."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-018397","json":"https://secwatch.observer/filing/0001628280-26-018397.json","markdown":"https://secwatch.observer/filing/0001628280-26-018397.md","text":"https://secwatch.observer/filing/0001628280-26-018397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026018397/0001628280-26-018397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026018397/dtil-20260317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:17:24.818741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}